Vol 55, No 3 (2024)
Review article
Published online: 2024-06-12
Current knowledge and management of primary mediastinal large B-cell lymphoma
1
, 1, 2, 1
, 1, 2, 1
DOI: 10.5603/ahp.99320
Acta Haematol Pol 2024;55(3):137-144.
Abstract
Primary mediastinal large B-cell lymphoma (PMBCL) is a rare subtype of non-Hodgkin’s lymphoma that predominantly affects young females. Despite advances in the understanding of its biology, there is still no consensus on the optimal treatment strategy. First-line regimens such as R-CHOP and DA-EPOCH-R result in 2-year progression-free survival (PFS) rates of c.80% and overall survival (OS) rates of c.90%. However, the role of radiotherapy as a consolidation treatment remains unclear, with some studies suggesting limited benefits for patients with negative PET scans at the end of treatment. In cases of relapse or refractoriness, second-line therapies are comparable to those employed in the treatment of diffuse large B-cell lymphoma. Autologous stem cell transplantation remains a crucial salvage option, with 3-year OS and PFS rates of c.65% and 60%, respectively. New treatment approaches, including immune checkpoint inhibitors (e.g. pembrolizumab and nivolumab), chimeric antigen receptor-T (CAR-T) cell therapy, and bispecific antibodies, have demonstrated promising results. Further research into novel molecular targets and treatment combinations is necessary to improve clinical outcomes and minimize treatment-related toxicities in PMBCL.
Keywords: primary mediastinal large B-cell lymphomaCAR-Tradiotherapyrefractory disease
References
- Campo E, Swerdlow SH, Harris NL, et al. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011; 117(19): 5019–5032.
- Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization Classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022; 36(7): 1720–1748.
- Campo E, Jaffe ES. Taking gray zone lymphomas out of the shadows. Blood. 2021; 137(13): 1703–1704.
- Grant C, Dunleavy K, Eberle FC, et al. Primary mediastinal large B-cell lymphoma, classic Hodgkin lymphoma presenting in the mediastinum, and mediastinal gray zone lymphoma: what is the oncologist to do? Curr Hematol Malig Rep. 2011; 6(3): 157–163.
- Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med. 2003; 198(6): 851–862.
- Ahmed Z, Afridi SS, Shahid Z, et al. Primary mediastinal B-cell lymphoma: a 2021 update on genetics, diagnosis, and novel therapeutics. Clin Lymphoma Myeloma Leuk. 2021; 21(11): e865–e875.
- Wang Y, Chen M, Ni C, et al. Case report: primary mediastinal large B-cell lymphoma invasion of extranodal thyroid tissue mimicking tuberculosis and confounded by similar ultrasonic appearance. Front Oncol. 2022; 12: 879295.
- Martelli M, Ferreri A, Di Rocco A, et al. Primary mediastinal large B-cell lymphoma. Crit Rev Oncol Hematol. 2017; 113: 318–327.
- van Besien K, Kelta M, Bahaguna P. Primary mediastinal B-cell lymphoma: a review of pathology and management. J Clin Oncol. 2001; 19(6): 1855–1864.
- Martelli M, Ferreri A, Di Rocco A, et al. Primary mediastinal large B-cell lymphoma. Crit Rev Oncol Hematol. 2017; 113: 318–327.
- Papageorgiou SG, Diamantopoulos P, Levidou G, et al. Isolated central nervous system relapses in primary mediastinal large B-cell lymphoma after CHOP-like chemotherapy with or without Rituximab. Hematol Oncol. 2013; 31(1): 10–17.
- Dabrowska-Iwanicka A, Walewski JA. Primary mediastinal large B-cell lymphoma. Curr Hematol Malig Rep. 2014; 9(3): 273–283.
- Aoki T, Izutsu K, Suzuki R, et al. Novel prognostic model of primary mediastinal large B-cell lymphoma (PMBL): a multicenter cooperative retrospective study in Japan. Blood. 2013; 122(21): 638–638.
- Camus V, Rossi C, Sesques P, et al. Outcomes after first-line immunochemotherapy for primary mediastinal B-cell lymphoma: a LYSA study. Blood Adv. 2021; 5(19): 3862–3872.
- Ondrejka SL, Ott G. How I diagnose primary mediastinal (thymic) large B-cell lymphoma. Am J Clin Pathol. 2021; 156(4): 497–512.
- Pileri SA, Zinzani PL, Gaidano G, et al. International Extranodal Lymphoma Study Group. Pathobiology of primary mediastinal B-cell lymphoma. Leuk Lymphoma. 2003; 44 Suppl 3: S21–S26.
- Gibson SE, Dojcinov S, Dotlic S, et al. Mediastinal large B cell lymphoma and surrounding gray areas: a report of the lymphoma workshop of the 20th meeting of the European Association for Haematopathology. Virchows Arch. 2023; 483(6): 733–749.
- Dorfman DM, Shahsafaei A, Alonso MA. Utility of CD200 immunostaining in the diagnosis of primary mediastinal large B cell lymphoma: comparison with MAL, CD23, and other markers. Mod Pathol. 2012; 25(12): 1637–1643.
- Copie-Bergman C, Plonquet A, Alonso MA, et al. MAL expression in lymphoid cells: further evidence for MAL as a distinct molecular marker of primary mediastinal large B-cell lymphomas. Mod Pathol. 2002; 15(11): 1172–1180.
- Viganò E, Gunawardana J, Mottok A, et al. Somatic IL4R mutations in primary mediastinal large B-cell lymphoma lead to constitutive JAK-STAT signaling activation. Blood. 2018; 131(18): 2036–2046.
- Szydłowski M, Dębek S, Prochorec-Sobieszek M, et al. PIM kinases promote survival and immune escape in primary mediastinal large B-cell lymphoma through modulation of JAK-STAT and NF-κB activity. Am J Pathol. 2021; 191(3): 567–574.
- Chen H, Pan T, He Y, et al. Primary mediastinal B-cell lymphoma: novel precision therapies and future directions. Front Oncol. 2021; 11: 654854.
- Bhatt VR, Mourya R, Shrestha R, et al. Primary mediastinal large B-cell lymphoma. Cancer Treat Rev. 2015; 41(6): 476–485.
- Steidl C, Connors JM, Gascoyne RD. Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment. J Clin Oncol. 2011; 29(14): 1812–1826.
- NCCN Guidelines® Updates: T-Cell Lymphomas. J National Compr Cancer Netw. 2022; 20(3).
- Vitolo U, Seymour JF, Martelli M, et al. ESMO Guidelines Committee. Extranodal diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016; 27(suppl 5): v91–v9v102.
- Cwynarski K, Marzolini MAV, Barrington SF, et al. British Society for Haematology Guidelines. The management of primary mediastinal B-cell lymphoma: a British Society for Haematology Good Practice Paper. Br J Haematol. 2019; 185(3): 402–409.
- Zhou H, Xu-Monette ZY, Xiao L, et al. Prognostic factors, therapeutic approaches, and distinct immunobiologic features in patients with primary mediastinal large B-cell lymphoma on long-term follow-up. Blood Cancer J. 2020; 10(5): 49.
- Shah NN, Szabo A, Huntington SF, et al. R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis. Br J Haematol. 2018; 180(4): 534–544.
- Savage KJ. Primary mediastinal large B-cell lymphoma. Blood. 2022; 140(9): 955–970.
- Dunleavy K, Pittaluga S, Maeda LS, et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med. 2013; 368(15): 1408–1416.
- Chan EH, Koh LP, Lee J, et al. Real world experience of R-CHOP with or without consolidative radiotherapy vs DA-EPOCH-R in the first-line treatment of primary mediastinal B-cell lymphoma. Cancer Med. 2019; 8(10): 4626–4632.
- Zucca E, Davies A, Kryachok I, et al. Observation vs. radiotherapy in primary mediastinal B-cell lymphoma patients with complete response to standard immunochemotherapy: The IELSG37 randomized trial. J Clin Oncol. 2023; 41(17_suppl): LBA7505–LBA7505.
- Polgarova K, Janíková A, Belada D, et al. Survival of patients with primary mediastinal B-cell lymphoma treated by immunochemotherapy with or without radiotherapy. Blood. 2022; 140(Supplement 1): 3831–3832.
- Vassilakopoulos TP, Piperidou A, Mellios Z, et al. PET for response assessment to R-da-EPOCH inpPrimary mediastinal large B-cell lymphoma: who is worthy to be irradiated? Hemasphere. 2023; 7(11): e965.
- Vassilakopoulos TP, Pangalis GA, Katsigiannis A, et al. Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy in primary mediastinal large B-cell lymphoma: the emerging standard of care. Oncologist. 2012; 17(2): 239–249.
- Lisenko K, Dingeldein G, Cremer M, et al. Addition of rituximab to CHOP-like chemotherapy in first line treatment of primary mediastinal B-cell lymphoma. BMC Cancer. 2017; 17(1): 359.
- Savage KJ, Al-Rajhi N, Voss N, et al. Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience. Ann Oncol. 2006; 17(1): 123–130.
- Zinzani PL, Stefoni V, Finolezzi E, et al. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study. Clin Lymphoma Myeloma. 2009; 9(5): 381–385.
- Aoki T, Shimada K, Suzuki R, et al. High-dose chemotherapy followed by autologous stem cell transplantation for relapsed/refractory primary mediastinal large B-cell lymphoma. Blood Cancer J. 2015; 5(12): e372.
- Hayden AR, Tonseth P, Lee DG, et al. Outcome of primary mediastinal large B-cell lymphoma using R-CHOP: impact of a PET-adapted approach. Blood. 2020; 136(24): 2803–2811.
- Camus V, Rossi C, Sesques P, et al. Outcomes after first-line immunochemotherapy for primary mediastinal B-cell lymphoma: a LYSA study. Blood Adv. 2021; 5(19): 3862–3872.
- Vardhana S, Hamlin PA, Yang J, et al. Outcomes of relapsed and refractory primary mediastinal (thymic) large B cell lymphoma treated with second-line therapy and intent to transplant. Biol Blood Marrow Transplant. 2018; 24(10): 2133–2138.
- Milpied N, Deconinck E, Gaillard F, et al. Groupe Ouest-Est des Leucémies et des Autres Maladies du Sang. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med. 2004; 350(13): 1287–1295.
- Nademanee A, Molina A, O'Donnell MR, et al. Results of high-dose therapy and autologous bone marrow/stem cell transplantation during remission in poor-risk intermediate- and high-grade lymphoma: international index high and high-intermediate risk group. Blood. 1997; 90(10): 3844–3852.
- Poiré X, van Besien K. Autologous transplant for primary mediastinal B-cell lymphoma. Expert Rev Hematol. 2009; 2(1): 31–36.
- Camus V, Bigenwald C, Ribrag V, et al. Pembrolizumab in the treatment of refractory primary mediastinal large B-cell lymphoma: safety and efficacy. Expert Rev Anticancer Ther. 2021; 21(9): 941–956.
- Zinzani PL, Thieblemont C, Melnichenko V, et al. Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170.. Blood. 2023; 142: 141–145.
- Zinzani PL, Santoro A, Gritti G, et al. Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-up. Blood Adv. 2023; 7(18): 5272–5280.
- Benmebarek MR, Karches CH, Cadilha BL, et al. Killing mechanisms of chimeric antigen receptor (CAR) T cells. Int J Mol Sci. 2019; 20(6): 1283.
- Chen YJ, Abila B, Mostafa Kamel Y. CAR-T: what is next? Cancers (Basel). 2023; 15(3): 663.
- Locke FL, Miklos DB, Jacobson CA, et al. All ZUMA-7 Investigators and Contributing Kite Members. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med. 2022; 386(7): 640–654.
- Crombie JL, Nastoupil LJ, Redd R, et al. Real-world outcomes of axicabtagene ciloleucel in adult patients with primary mediastinal B-cell lymphoma. Blood Adv. 2021; 5(18): 3563–3567.
- Abramson JS, Solomon SR, Arnason J, et al. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study. Blood. 2023; 141(14): 1675–1684.
- Vercellino L, Di Blasi R, Kanoun S, et al. Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma. Blood Adv. 2020; 4(22): 5607–5615.
- Calvez BLe, Tessoulin B, Renaud L, et al. Outcomes of allogeneic hematopoietic cell transplantation (allo-HCT) for adults with primary mediastinal B cells lymphoma (PMBCL): a retrospective study on behalf of the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) and the Lymphoma Study Association (LYSA) group. Blood. 2021; 138(Supplement 1): 1826–1826.
- Zurko J, Ramdial J, Shadman M, et al. Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma. Haematologica. 2023; 108(1): 98–109.
- Dickinson MJ, Carlo-Stella C, Morschhauser F, et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2022; 387(24): 2220–2231.
- Thieblemont C, Phillips T, Ghesquieres H, et al. Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I/II trial. J Clin Oncol. 2023; 41(12): 2238–2247.
- Kurtz DM, Scherer F, Jin MC, et al. Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma. J Clin Oncol. 2018; 36(28): 2845–2853.
- Jimenez-Ubieto A, Poza M, Martín-Muñoz A, et al. Potential utility of circulating tumor DNA monitoring in primary mediastinal B-cell lymphoma treated with R-DA-EPOCH. Blood. 2021; 138(Supplement 1): 4491–4491.